Answers are grounded in this paper and cite their sources.
Antimicrobial resistance is a pressing global health threat, yet the state of the antibacterial pipeline is frequently judged by approval counts alone—a metric that can obscure whether new products represent genuine pharmacological innovation. This mini review examines the antibacterial-containing agents approved by the U.S. Food and Drug Administration (FDA) between 2018 and the first half of 2026, drawing on the FDA’s annual novel-drug approval reports, the corresponding approved product labels, and the primary literature. Over this period, 18 antibacterial-containing agents were approved—fewer than 5% of all FDA approvals—of which 15 are are intended for systemic therapy. To move beyond a simple count, we classify these approvals using an innovation framework defined by mechanism of action, chemical class, molecular target, bacterial entry strategy, protective-combination logic, and formulation design. Results show that the post-2018 record is dominated by incremental optimisation of established classes (tetracyclines, aminoglycosides) and by protective β-lactam/β-lactamase-inhibitor combinations. Strong discovery-relevant innovations remain the exception: two new chemical classes that act through distinct binding modes on validated topoisomerase targets (gepotidacin and zoliflodacin), the first pleuromutilin approved for systemic use (lefamulin), and a new bacterial entry strategy within an established class (cefiderocol). We conclude that the post-2018 record shows a partial recovery in FDA approval numbers that has not been accompanied by a proportionate expansion of the chemical and mechanistic space of approved products; approval counts alone cannot demonstrate a renewal of antibacterial discovery. We argue that a pharmacology-centred reading of the approval record is more informative than the count itself.
No takes yet. Share an insight, caveat, or question.
Campanini-Salinas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: